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Abstract: CD146 (MCAM, MUC18, S-Endo1) is a transmembrane glycoprotein belonging to both
CAM and mucin families. It exists as different splice variants and is cleaved from the membrane by
metalloproteases to generate a soluble form. CD146 is expressed by numerous cancer cells as well as
being one of the numerous proteins expressed by the vascular endothelium. It has also been identified
on smooth muscle cells, pericytes, and some immune cells. This protein was initially described
as an actor involved in tumor growth and metastatic dissemination processes. Some recent works
highlighted the role of CD146 in angiogenesis. Interestingly, this knowledge allowed the development
of therapeutic and diagnostic tools specifically targeting the different CD146 variants. The first anti-
CD146 antibody designed to study the function of this molecule, MUC18, was described by the Pr.
J.P. Jonhson in 1987. In this review, we will discuss the 30 following years of research focused on the
detection, study, and blocking of this protein in physiological and pathological processes.
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1. Introduction
Cluster of differentiation 146 (CD146) also named melanoma cell associated molecule (MCAM)/
Mucin 18 (MUC18)/S-Endo 1 was first discovered in metastatic melanoma and its expression was
rapidly associated to a bad prognosis. Since this initial discovery, CD146 was found to be upregulated
in many cancer types. Thereafter, CD146 was also identified on endothelial cells where it is involved
in angiogenesis. Angiogenesis, which corresponds to the formation of new blood vessels from pre-
existing vessels, largely contributes to tumor development. The identification of new proteins and cells
involved in the development and dissemination of tumors remains an important challenge to generate
diagnostic and therapeutic tools. For several decades, studies have highlighted CD146 as a key actor of
tumor growth and angiogenesis. CD146 displays different isoforms and could thus constitute a novel
therapeutic target. Many studies describe structural features, localization, and functions of CD146 in
the vascular endothelium and tumor cells. The timeline of research on CD146 is presented in Figure 1.
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Figure 1. Timeline of research on CD146. This timeline represents the principal discoveries (in green) 
and antibodies (in blue) related to CD146 [1–14]. 
This review will now focus on the role of the different isoforms of CD146 with a particular 
interest in the diagnostic and therapeutic tools targeting the molecule. 
2. Description and Cellular Localization of CD146 
2.1. Genomic Description of CD146 
The CD146 gene is located specifically on the arm q23.3 of chromosome 11 in humans and on 
chromosome 9 in mice. The gene encoding the CD146 protein extends over 14kb. CD146 structure is 
composed of five immunoglobulin-like domains, two variable domains of V2 type, and three constant 
domains of C2 type, but also a transmembrane domain and an intracytoplasmic portion [15]. The 
extracellular part of the molecule, including the five immunoglobulin domains, is encoded by 13 
exons. The transmembrane and intracellular domains are encoded by three exons. 
The promoter of CD146 presents different putative binding sites and motifs including AP1, AP-
2, cAMP Response Element (CRE), SP1, CArG, and c-myb. Analysis of this DNA segments suggests 
that the four SP-1 sites, the two AP-2 domains, and one response element to Adenosine 
MonoPhosphate cyclic (AMPc)-(CRE) form the minimal promotor of CD146 [16]. Specific sites play 
a role in CD146 expression. The AP-2 sites which are located at −131 and −302 by relative to the initial 
ATG, reduced promoter activity by 70% and 44%, respectively [16]. Moreover, when mutated, the 
CRE site inhibits by 70% the transcription of the gene. Therefore, AP-2 [17] and CRE sites [18] have 
been described to modulate CD146 expression in melanoma cells, leading to an increase in tumor 
growth and metastatic potential in these cancers. In fact, the AP-2 binding site located in the promoter 
(located at −23 bp) is an inhibitor of the transcription of CD146 while the other AP-2 sites (located 
respectively at −131, −302, and −505) are transcription activators [16,17]. 
The CD146 mRNA has been first identified in human melanoma cancer cells and represents 3.3 
Kb [19]. Its encoding region is about 1940 bp. There exists a strong homology between the human 
and mouse mRNA sequences, but several differences can be noted. In humans, there is a lengthening 
of the 3’ and 5′ Untranslated Transcribed Region (5’ UTR) region as wells as a loss of 6pb in exon 2. 
The encoding regions and 5′UTR region have a homology of about 80% and 72%, respectively, 
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Figure 1. Timeline of research on CD146. This timeline represents the principal discoveries (in green)
and antibodies (in blue) related to CD146 [1–14].
This review will now focus on the role of the different isoforms of CD146 with a particular interest
in the diagnostic and therape tic tools targeting the molecule.
2. Description and Cellular Localization of CD146
2.1. Genomic Descriptio of CD146
The CD146 gene is located specifically on the arm q23.3 of chromosome 11 in humans and on
chromosome 9 in mice. The gene encoding the CD146 protein extends over 14kb. CD146 structure
is composed of five immunoglobulin-like domai s, two variable domains of V2 type, and three
constant domains of C2 type, but also a transmembrane domain and an intracytoplasmic portion [15].
The extracellular part of the molecule, including the five immunoglobulin domains, is encoded by
13 exons. The transmembrane and intracellular domains are enc ded by three exons.
The promoter of CD146 presents different putative binding sites and motifs including AP1, AP-2,
cAMP Response Element (CRE), SP1, CArG, and c-myb. Analysis of this DNA segments suggests that
the four SP-1 sites, the two AP-2 domains, and one response element to Adenosine MonoPhosphate
cyclic (AMPc)-(CRE) form the m nimal promotor of CD146 [16]. Specifi sites play a r le in CD146
expression. The AP-2 sites which are located at −131 and −302 by relative to the initial ATG, reduced
promoter activity by 70% and 44%, respectively [16]. Moreover, when mutated, the CRE site inhibits
by 70% the transcription of the gene. Therefore, AP-2 [17] and CRE sites [18] have been described to
modulate CD146 expression in melanoma cells, l ading to an increase in tumor growt and metastatic
potential in these cancers. In fact, the AP-2 binding site located in the promoter (located at −23 bp)
is an inhibitor of the transcription of CD146 while the other AP-2 sites (located respectively at −131,
−302, and −505) are transcription activators [16,17].
The CD146 mRNA has been first identified in human melanoma cancer cells and represents
3.3 Kb [19]. Its encoding region is about 1940 bp. There exists a strong homology between the human
and mouse mRNA sequences, but several differences can be noted. In humans, there is a lengthening
of the 3’ and 5’ Untranslated Transcribed Region (5’ UTR) region as wells as a loss of 6pb in exon
2. The encoding regions and 5′UTR region have a homology of about 80% and 72%, respectively,
between the murine and human genes and there is only 31% of homology for the 3′UTR region. Finally,
the protein sequence has about 76% homology between these two species [1,20].
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There is one polymorphism concerning CD146 which has been described. In fact, rs3923594
polymorphism is associated with stages, metastasis, and recurrence in clear cell renal cell carcinoma in
the Chinese population [21].
2.2. CD146 Protein Structure and Isoforms
The CD146 protein sequence derived from the coding region has a theoretical molecular weight
of about 72 kilodaltons. However, CD146 molecular weight is around 113 kilodaltons. This difference
is due to the glycosylation sites which are present on the protein sequence. In fact, glycosylations
represent approximately 35% of the total molecular weight of the protein with mostly N-glycosylations.
The presence of sialylation has also been shown [22].
As a member of the immunoglobulin superfamily, CD146 displays many similarities in the
structure with BCAM (B-cell adhesion molecule) and ALCAM (activated leukocyte cell adhesion
molecule), but also many similarities in functions and expression in tumor and endothelial cells [23].
A short isoform and a long isoform have been identified for membrane CD146. These two isoforms
are generated by alternative splicing on exon 15 causing a reading frame shift. In 1987, the long isoform
was discovered in human melanoma and, more recently, the short isoform was identified as
a complementary DNA from chicken [24]. In addition to these two membrane isoforms, a soluble form
of CD146 was identified in human endothelial cell culture supernatant (HUVEC) and in the bloodstream
of patients [2].
The extracellular portion of both membrane isoforms of CD146 is similar. The difference is located
in the intracytoplasmic portion [24]. In fact, the intracytoplasmic domain of the short isoform is shorter
and contains a PDZ-binding domain and a phosphorylation site for protein kinase C. The long isoform
is composed of an endocytosis signal sequence and two Protein Kinase C (PKC) phosphorylation
domains [24].
Both mice and human intracytoplasmic domain sequences are similar at 95% and 93% for the
short isoform and long isoform, respectively. This conservation across species is in accordance with
the important functions carried by the intracytoplasmic domain of CD146.
Finally, identified for the first time in 1998 [2], a soluble form of CD146 with a molecular mass
around 100 Kilodaltons was detected in human plasma [25], resulting from a metalloprotease-dependent
shedding of the extracellular domain [26].
2.3. Cellular Localization of CD146
In CD146-positive cancer cells, both isoforms of CD146 are expressed but their precise localization
remains to be defined.
CD146 localization was essentially studied in endothelial cells. The localization of short and
long membrane CD146 isoforms is different. The long isoform of CD146 is expressed at the
intercellular junctions. Co-staining between CD146 and VE-cadherin, Focal Adhesion Kinase (FAK),
Platelet Endothelial Cell Adhesion Molecule (PECAM), and the catenin/cadherin complex shows no
co-localization, suggesting that the long isoform of CD146 is not located in the adherent junctions,
tight junctions, or focal adhesion sites [27,28]. An immunohistochemical staining of this isoform in
endothelial colony forming cells (ECFC) confirmed the junctional localization of this protein. Moreover,
the presence of a cytoplasmic pool of long CD146 that can be redistributed to the cell membrane was
also evidenced [3]. Overexpression of the long isoform of CD146 in MDCK cell line (Madin–Darby
canine kidney) showed a baso-lateral localization of the protein and this localization was dependent
on the presence of a di-leucine motif on its intracytoplasmic peptide sequence [27].
In contrast, short CD146 shows an apical localization in ECFC [3]. An apical localization was also
evidenced in MDCK cells [27]. Short CD146 isoform is involved during the first step of angiogenesis
process. It is involved in the adhesion, migration, and proliferation of endothelial cells [3].
The confluence of the endothelial monolayer constitutes a regulator of the cellular distribution
of the two membrane isoforms. Indeed, in non-confluent endothelial cells, the long isoform was
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localized in the cytoplasm and was not detected at the cell membrane. Concerning the short CD146
isoform, it was localized in the nucleus and at the migration front in non-confluent cells [3]. In other
experiments performed on chickens, results showed that the long isoform of CD146 was preferentially
localized in the microvilli where the protein plays a role in their formation [29].
3. CD146 in Cancer Cells
CD146 has been identified for the first time in melanoma where it plays an important role
in the disease progression. Thereafter, CD146 has been shown to be expressed in various cancers,
such as pancreatic, breast, prostate, ovarian, lung, kidney cancers, osteosarcoma, Kaposi sarcoma,
angiosarcoma, Schwann cell tumors, children and adult acute B cell lymphoblastic leukemia,
or leiomyosarcoma [30]. The mechanism of this neo-expression is still largely unknown but, in prostate
cancer, it was reported that high expression of CD146 resulted from hypermethylation at the promoter
of the CD146 gene [31]. A strong correlation was found between the increased metastatic capacities
of tumor cells and the increased expression of this molecule [32]. CD146 expression in human
melanoma cell lines correlates strongly with their ability to form primary tumors and to generate
distant metastasis in both immunodeficient nude and Severe Combined ImmunoDeficiency (SCID) [33].
As an example, CD146 expression increased melanoma cell metastasis in lung in nude mice after
intravenous injection [34]. These results were confirmed by using interfering RNA directed against
CD146 which decreased migration, proliferation, and invasion of melanoma cells in vitro [35].
Different cancer markers were analyzed in the early and late stages of patients with melanoma.
CD146 was the only protein in blood sample analysis which correlated with the advanced stages of
the cancer [36]. This finding was confirmed in another study where CD146 constituted a marker of
poor prognosis and survival in melanoma patient. It was concluded that CD146 was a better marker of
disease progression than analysis of sentinel lymph node on biopsies [37].
Likewise, in prostate cancer, CD146 overexpression increased tumor growth, invasiveness,
and metastatic potential [38]. This result was confirmed in biopsies of patients where CD146 overexpression
was also observed. In this study, CD146 expression was correlated with a poor prognosis. CD146 expression
was also correlated with an increase in the metastatic potential in ovarian carcinoma. Furthermore,
inhibition of CD146 protein expression in ovarian cancer cell lines inhibited invasiveness and tumor spread,
and induced apoptosis. This was explained by the fact that a lack of CD146 induced a decreased activity of
Rho GTPase [39] which is involved in these processes.
In breast cancer, it was first reported that CD146 could act as a tumor suppressor [40] while more
recent studies have described CD146 as a poor prognosis marker [41]. Indeed, over-expression of CD146
in a breast cancer cell line increased both motility and tumorigenicity [42]. This result was confirmed
in vivo.CD146 expression was correlated with markers of EMT in both gastric and breast cancer patient
biopsies [43,44]. This is due to the fact that CD146 induced the epithelial–mesenchymal transition (EMT)
in gastric and breast cancer cells in vitro. In triple negative breast cancers, the increased expression of
CD146 in epithelial cells induced a loss of epithelial markers and an increase in mesenchymal markers
expression, leading to increased invasiveness, migration, and mammospheres formation. In this study,
it was shown that CD146 induced an increased expression of CD44 but also a decreased expression of
CD24 on the cell membrane suggesting that cancer cells acquire a cancer stem cell-like phenotype [45].
It is important to note that all the mechanisms involved in melanoma progression are not still
understood. A recent study showed that a B lymphocyte subpopulation, called B1 lymphocytes,
displayed a pro-metastatic potential. In fact, a decrease of both tumor growth and metastatic
dissemination was observed after depletion of this cellular population in an experimental metastatic
model. The homophilic interaction between the B lymphocytes and the cancer cells, through CD146,
was responsible for the metastatic dissemination [46]. Moreover, the expression of CD146 at the cell
membrane of cancer cells was increased when these cells were co-cultured with the B1 lymphocytes,
leading to an increase in the number of metastasis.
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A recent study reported that cancer cells expressing CD146 were able to secrete soluble
CD146 in vitro and in vivo [4]. This phenomenon was described in melanoma, colorectal cancer,
and pancreatic cancer cell lines by Enzyme-Linked ImmunoSorbent Assay (ELISA). The authors
demonstrated that soluble CD146 secreted by cancer cells induced both autocrine effects on cancer
cells and paracrine effects on vascular endothelial cells. Furthermore, cancer cells stimulated in vitro
with recombinant soluble CD146 were more proliferative and produced more pro-tumorigenic and
angiogenic factors, such as Vascular Endothelial Growth Factor (VEGF). The authors demonstrated
that soluble CD146 induced an anti-apoptotic phenotype in cancer cells and that it could also decrease
cancer cell senescence visualized by beta-galactosidase staining. The c-myc signaling pathway was also
upregulated by soluble CD146 confirmed by an increased protein expression of c-myc, phospo-c-myc
on residue ser62 and max, a partner of c-myc. Finally, they also showed that soluble CD146 secreted
by cancer cells increased endothelial cell proliferation and tumor angiogenesis. These pro-angiogenic
and anti-apoptotic effects were confirmed in vivo in different models of xenografted mice.
In line with this result, an increased concentration of soluble CD146 in blood of patients with
non-small cell lung cancer has been described, as compared to control patients or patients with
respiratory inflammatory disease [47]. Altogether, these results show that soluble CD146 also plays
a major role in tumor development and angiogenesis.
4. CD146 in Angiogenesis; Immunity and Inflammation
Initiation and progression of cancer are closely linked to angiogenesis, immunity, and inflammation.
Of interest, CD146 is expressed in many cells involved in these different processes.
Angiogenesis plays a major role in tumor development. Endothelial cells which display
angiogenic properties can proliferate, migrate, adhere, and generate new capillaries from pre-existing
vessels. The discovery of the existence of the two membrane isoforms of CD146 and the
description of a soluble form of CD146 led to study their implications during angiogenesis. Using
specific siRNA directed against the two membrane isoforms, it has been shown that the absence
of short CD146 in endothelial cells decreased cellular proliferation, migration, and adhesion.
Conversely, its overexpression displayed opposite effects. In contrast, the absence of long CD146
isoform destabilized the junctions of neo-vessels which were necessary to generate pseudo-capillaries
in matrigel in vitro. So, both short and long CD146 isoforms display complementary effects for
the generation of neo-vessels. The pro-angiogenic effect of short CD146 was confirmed in vivo
by transplantation of ECFC over-expressing this protein in a mouse model of hind limb ischemia.
An increase in both ECFC incorporation in ischemic muscle and neo-vessel generation was observed [3].
Recent works showed that the short isoform of CD146 was associated with different proteins at
the membrane of endothelial cells including VEGF-R2 [48], angiomotin, and VEGF-R1 [48–50].
This association seems to be essential for the activation and function of these different pathways.
Indeed, the absence of short CD146 isoform decreased both phosphorylation of VEGF-R2 and
pro-angiogenic effects of VEGF in endothelial cells. It was also recently shown that Galectin
3 constituted a new partner for CD146 in endothelial cells and that this association induced a
dimerization of CD146 at the cell surface, leading to the activation of several pathways. Among
them, the AKT pathway leads to the secretion of metastasis-promoting cytokines [51]. Finally, it has
also been shown that soluble CD146 displayed a pro-angiogenic activity. Soluble CD146 was able to
increase the formation of pseudo-capillaries in vitro but also to induce neo-vascularization in a rat
model of hindlimb ischemia. Moreover, recruitment of mature and immature endothelial cells but also
smooth muscle cells was increased in matrigel plugs containing soluble CD146 in mice, leading to the
formation of capillary-like structures [5]. Interestingly, it was shown that soluble CD146 stimulated
short CD146 isoform through its binding on angiomotin [49] and that the angiogenic properties of
soluble CD146 were additive to those of VEGF [5].
CD146 is also expressed in approximately 1% of blood mononuclear cells of peripheral blood in
healthy patients. More precisely, a flow cytometry analysis of the different lymphocyte populations
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showed that CD146 was expressed on a sub-population of B and T human lymphocytes [52]. About 1%
of B lymphocytes express CD146 and its expression is upregulated by different cytokines such as
IL-4 and CD40. In addition, CD146 can be neo-expressed on some immune cell populations after
stimulation [52]. These results have been deepened by using two antibodies generated in rat. Using the
HUT102 T lymphocytic cell line, CD146 was shown to be expressed on 2% of CD3+, CD3+/CD4+,
and CD3+/CD8+ lymphocytes. Here again, stimulations with cytokines such as IL-2 [52] and PHA
(phytohemagglutinin) [53] increased the amount of CD146+ T lymphocytes. These cells were also
found in vivo in the synovial fluid of patients with rheumatoid arthritis [53]. In mouse, a leucocyte
screening was carried out and demonstrated that both T/B lymphocytes, monocytes, and dendritic
cells did not express CD146. Moreover, it was also demonstrated that CD146 was expressed by 30%
of neutrophils and 60% of Natural Killer (NK) cells. Furthermore, there was a correlation between
expression of CD146 and an increased expression of CD11b and CD27 which reflected the NK maturity.
The CD146 positive NK produced gamma interferon in smaller quantities and also had a decreased
cytotoxic capacity [54].
Different studies have reported that CD146 is also involved in inflammation, and in particular in
leukocyte transmigration [6]. Using both a monocyte cell line, THP-1, and freshly isolated monocytes,
it was shown that CD146 modulated monocyte transmigration. Indeed, junctional CD146 expressed
by endothelial cells bound to monocytes through a heterophillic interaction in order to increase
their transmigration. Furthermore, monocyte transmigration was increased after a stimulation
with soluble CD146 [6]. In addition, an increased adhesion capacity of CD146+ T lymphocytes
was observed after stimulation with IL-1 beta. This effect was blocked by adding an anti-CD146
antibody [55]. An inflammatory stimulus could also increase the adhesion of CD4+/CD146+ T
lymphocytes on endothelium. In this study, transfection of the long isoform of CD146 in NKL.1
cell line reduced the number of rolling cells and increased their adhesion to endothelial monolayer.
Furthermore, an increase in microvillis in T lymphocyte cell membrane was observed. An increased
transmigration of lymphocytes through HMVECs (human microvascular endothelial cells) monolayer
following incubation with an anti-CD146 antibody (P1H12) was reported in another study [56]. Finally,
a co-expression of CD146 and CCR6 was demonstrated in a population of TH17 lymphocytic cells [57].
5. Approaches for Therapeutic Targeting of CD146
In view of the major role of CD146 in tumor pathologies, different antibodies have been generated.
These different antibodies, their utilization and their generation are summarized in Table 1.
In 1987, Pr. J.P. Jonhson identified CD146 as a marker of melanoma progression by using
an antibody (called MUC18) generated by mouse immunization with a cell lysate of metastazing
melanoma [58].
Later, the team of Pr. F. Dignat-George identified CD146 as a new marker of circulating endothelial
cells in the blood by flow cytometry. This result was obtained by the generation of a mouse monoclonal
antibody named Sendo-1 [7] obtained by mice immunization with a HUVEC lysate [59,60].
Since these pioneer antibodies, different antibodies directed against CD146 have been generated
in order to block its functions. The first one, named ABX -MA1, was able to recognize the human
form of CD146. It could inhibit the formation of spheroids containing melanoma cells and could
reduce metastasis, tumorigenicity, and vascularization of tumors in vivo. These effects were due to
the inhibition of MMP-2 expression and activity that was involved in metastasis dissemination [8].
In another model of immunodeficient mouse, injection of ABX-MA1 significantly decreased metastatic
dissemination of cells derived from human osteosarcoma in lung [61].
Another strategy was developed to target tumor stromal cells. To this end, monoclonal antibodies
specifically directed against the vascular endothelium of tumors were generated. During the antibody
screening, the authors focused on one antibody named AA98. AA98 mAb recognized CD146 expressed
on the intra-tumoral vasculature but not on the vasculature of healthy tissues [9]. This antibody
recognized CD146 and inhibited its activity. Indeed, the injection of AA98 mAb decreased the
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number by 70% the number of vessels in a chicken chorrioallantoic membrane assay. Moreover, AA98
antibody reduced tumor angiogenesis in xenografted tumors (hepatocellular carcinoma, pancreatic,
and leiomyosarcoma) in mice [36]. Following this first work, authors investigated the signaling
pathways altered by this antibody. They demonstrated that it modulated phosphorylation of
several kinases such as p38/MAPK, suppressed NFkB activation, and inhibited both MMP-9 and
ICAM-1 expression. These results suggested that inhibition of NFkB activity was a major point of
the inhibitory effects of AA98 and explained the decrease in cell migration, angiogenesis, and metastatic
dissemination [62].
Table 1. Description of available anti-CD146 antibodies.
Antibody Utilization Antibody generation
MUC 18 IHC, WB Mouse immunization with a cell lysate of metastazing melanoma(Lehmann JM et al., Cancer Research, 1987) [1].
S-endo 1 (Biocytex) IF, IHC, WB, FC Mouse immunization with a HUVEC lysate (George et al.,J. Immunol. Methods, 1991) [7].
7A4 (Biocytex) IF, WB, FC, ELISA, IP Mouse immunization with an injection of CD146
AA98 Bloquing in vivo, WB, IHC, IF,WB
Mouse immunization with a lysate of HUVEC stimulated with
conditioned medium of hepatoma cell line SMMC 7721
(Yan et al., Blood, 2003 ) [9].
ABX-MA1 WB, FC, IHC Generated using Abgenix’s proprietary XenoMouse mice(Mills et al„ Cancer Res., 2002) [8].
M2J-1 Bloquing in vivo, ELISA Rat immunization with an injection of recombinant soluble CD146(Stalin et al., Oncogene, 2016) [4].
TsCD146 IF, FC, WB, PET/SPECT-CT,bloquing in vivo
Rat immunization with an injection of recombinant soluble CD146
(Nollet et al., in process) [10].
YY146 PET/SPECT-CT Mouse immunization with an injection of the human CD146antigen (Yang et al., 2016, Proc Natl Acad Sci) [14].
OI-3 Radiolabeling, FC
Mouse immunization with an injection of recombinant chimeric
versions of human IgG1 or human IgG3 Fc sequences
(Westrøm et al, 2016, PLoS One) [11].
5G6 (Biocytex) IF Mouse immunization with an injection of immunopurified CD146
2F6 (Biocytex) IF Mouse immunization with an injection of immunopurified CD146
3D9 (Biocytex) IF, FC Mouse immunization with an injection of immunopurified CD146
Antibody against short or long
isoforms of CD146 WB, IF, FC, IP
Rabbit immunization with an injection of peptides corresponding
to the intracellular part of short and long CD146
(Kebir et al., Circulation research, 2010) [3].
P1H12 (Abcam) IF, IHC, WB, FC, IP, ELISA Mouse immunization with a HUVEC lysate(Solovey et al., J Lab Clin Med, 2001) [56]
EPR3208 (Abcam) IF, IHC, FC, WB Rabbit immunization with an injection of a synthetic peptidecorresponding to Human CD146 AA 600 to the C-terminus
541-10B2 (Miltenyi Biotec) FC Mouse immunization
AA1 WB Mouse immunization with CD146 purified from HUVEC(Zhang et al., Hybridoma, 2008) [63]
In this table are listed the different anti-CD146 antibodies, their characteristics and how they were generated.
IHC = immunohistochemistry, WB = Western blot, IF = immunofluorescence, FC = flow cytometry,
IP = immuno-precipitation, PET = positron emission tomography, ELISA = enzyme-linked immunosorbent assay,
SPECT-CT = single-photon emission tomography / computed tomography.
It is worth noting that AA98 mAb displayed additive inhibitory effects when used in combination
with bevacizumab (anti-VEGF antibody) in xenografted models of both human pancreatic and
melanoma tumors [64]. It also displayed synergistic inhibitory effects when associated with vorinostat
for the treatment of ovarian cancer [65]. Finally, this antibody significantly reduced colonic chronic
inflammation in a mouse model and prevented the development of cancer associated with the
inflammatory state [48]. Several antibodies were generated but they did not display therapeutic
effects (see Table 1).
Recently, a novel inhibitory antibody against the soluble form of CD146 was generated.
This antibody named M2J-1 is specific of the soluble form of CD146 [4]. The authors demonstrated that
M2J-1 antibody treatment was able to decrease tumor growth and angiogenesis in human melanoma
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and pancreatic tumors xenografted in immunodeficient mice. It could also induce tumor apoptosis
in vivo. The particularity of this antibody is that it does not bind to membrane CD146, limiting the side
effects of antibodies which also target CD146 expressed at the surface of the vascular endothelium.
Recently, a novel antibody specifically recognizing the tumor form of CD146 was generated.
This antibody, referred to as TsCD146 mAb, could detect CD146 in cancer cells but not in cells that express
the molecule in physiological conditions (endothelial cells, smooth muscle cells). TsCD146 mAb detects
specifically tumor CD146 in human biopsies and in animal models of xenografted tumor cells by positron
emission tomography (PET) imaging. In addition, TsCD146 mAb could specifically detect CD146-positive
cancer microparticles in the plasma of patients with melanoma. TsCD146 mAb also displayed therapeutic
effects since it could reduce the growth of human CD146-positive cancer cells xenografted in nude mice.
This effect was due, at least in part, to a decrease in the proliferation of CD146-positive cancer cells after
TsCD146-mediated internalization of the membrane CD146. This antibody could be of major interest
for diagnostic and therapeutic strategies against CD146-positive tumors in a context of personalized
medicine [10].
To date, there is only one humanized anti-CD146 antibody available. It has been developed by
Prothena Corporation plc (Nasdaq-PRTA, Dublin, Ireland) and it is named PRX003. It was used in
clinical trial for treatment of patients with psoriasis. The pharmacodynamics effects did not translate
into meaningful clinical benefit in patients with psoriasis treated with PRX003 (http://ir.prothena.com).
The targets of the different therapeutic anti-CD146 antibodies are indicated in Figure 2.
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Furthermore, a meta-analysis with 12 studies involving 2694 participants reveals that the
associations between CD146 overexpression and the outcome endpoints (overall survival or time
to progression) are statistically significant in Mongoloid and Caucasian patients with both lung and
digestive system cancer. Showing as well as CD146 could be a prognosis predictive biomarker [66].
6. New Approaches for Theranostic Targeting of CD146
Early detection of tumors constitutes the leading strategy to extend patient survival. Due to
the availability of different imaging technics, new concepts emerged for non-invasive diagnosis of
cancer using magnetic resonance imaging (MRI), computed tomography (CT), and contrast-enhanced
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ultrasound (CEUS) [67–69]. However, these imaging techniques allowed the detection of tumors
that are seldom visible during the first stages of development or tumors which are insensitive to
biological changes occurring soon after treatment [67–69]. These techniques are more efficient to
non-invasively detect both dysregulations of tumor-associated markers and variations in tumor
metabolism or in molecular pathways. Novel technologies, such as positron emission tomography
(PET) could improve tumor detection, but they need the identification of tumor-specific molecular
signatures and antigens. Therefore, the generation of targeted imaging agents with high affinity
for the selected molecule constitutes an important step. ImmunoPET exploits the binding affinity
and specificity of monoclonal antibodies and peptides for their cognate antigen and binding protein,
respectively, to detect tumor-associated proteins. It has been assessed that immunoPET has a better
sensitivity and specificity compared to MRI and PET [70].
In this way, CD146 has emerged as an attractive target for targeted diagnosis and therapy in cancer.
In very recent studies, CD146 detection by immunoPET imaging was described for several
types of tumors. By using a newly generated monoclonal antibodies named YY146, CD146 was
suggested as a new target for the early detection and better staging of hepatocellular carcinoma (HCC).
It could also be used for both monitoring of tumor response to CD146-immunotargeted therapies
and image-guided ablation of tumors for malignant brain cancer [71,72]. ImmunoPET imaging using
YY146 antibody coupled with 64Cu-NOTA or 89Zr-Df demonstrated the potential use of this radiotracer
for imaging lung [73] or brain [72] cancer, respectively, using different human lung cancer cell lines
in immunodeficient mice. Moreover, the intensity of labeling was proportional to the intensity of
expression of CD146 in these cell lines [73]. Another antibody targeting CD146, called OI-3, labeled
with 125-I or 177-Lu was also used to detect CD146 expression in osteosarcoma xenograft implanted
subcutaneously in nude mice [11].
7. Conclusions
The expression of CD146 is correlated with tumor growth and metastatic dissemination. Moreover,
the soluble form of CD146 secreted by both cancer and endothelial cells is involved in tumor growth
and angiogenesis. So, CD146 constitutes an important target for the early detection and treatment of
CD146-positive tumors in a context of personalized medicine. This is now well understood and many
diagnostic and/or therapeutic antibodies to CD146 were generated for this purpose.
Conflicts of Interest: The authors declare no conflict of interest.
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